MPN-RC 118 AVID200 in Myelofibrosis

NCT03895112 | Completed Phase 1 DMC FDA Drug

• 3 other identifiers: GCO 07-0548-01401P01CA108671MPN-RC 118
• Study Type: interventional
• Target: 21
• Locations: 1 country
• Sites: 1

Brief Summary

Increased levels of TGF-β1 were detected in serum, plasma and BM and positively correlated with both grade of BMF and extent of leukemic cell infiltration in the marrow. TGF-β likely plays a dual role in promoting myelofibrosis and myeloproliferation, both of which are the bone marrow morphologic hallmark of MF. AVID200 is a drug that targets TGF-β1 and TGF-β3. The study team hypothesizes that inhibiting the TGF-β signaling pathway in MF will decrease the fibrogenic stimuli leading to myelofibrosis and concomitantly interrupt myeloproliferation and restore normal hematopoiesis. This is a first in human, open-label, multicenter, Phase I/Ib trial of AVID200. Patients must have intermediate-2 or higher primary myelofibrosis (PMF), post-essential thrombocythemia or polycythemia-vera related MF (Post ET/PV MF). This study will enroll up to 24 patients. AVID200 is delivered by IV infusion on day 1 of each 3 week cycle.

Conditions

Primary Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post ET MF; Post PV MF

Keywords

Therapeutic; Fibrosis; Splenomegaly; Myeloproliferative neoplasms research consortium; Intravenous Infusion; Phase 1

Outcome Measures

Primary Outcomes (2)

• Maximally tolerated dose (MTD) of AVID200

  Cohorts of 3 patients with a maximum evaluable sample size of 12 patients and a target toxicity rate of 30% to estimate the MTD. Each cycle is 21 days.

  After 6 cycles (Each cycle is 21 days)

• Number of patients with response eligibility for Phase 1b

  Subjects attaining at least a CI (clinical improvement) by IWG/ELN criteria, or a decrease in bone marrow fibrosis by ≥1 grade with otherwise stable disease, will be allowed to continue AVID200 in the extension phase of the trial.

  After 6 cycles

Secondary Outcomes (4)

• IWG/ELN criteria

  After 6 cycles and after 12 cycles (Each cycle is 21 days)

• Bone marrow fibrosis grade

  up to 37 days after 13 cycles (Each cycle is 21 days)

• Myelofibrosis Symptom Assessment Form (MFSAF)

  up to 37 days after 13 cycles (Each cycle is 21 days)

• EORTC QLQ-C30

  up to 37 days after 13 cycles (Each cycle is 21 days)

Study Arms (1)

AVID200

EXPERIMENTAL

intravenous in dose cohorts of 70mg/m2 or 180 mg/m2

Drug: AVID200

Interventions

AVID200 DRUG

dose cohorts of 21-day cycles

AVID200

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Subjects must be ≥18 years of age at the time of signing the Informed Consent Form (ICF)
• Subjects must voluntarily sign an ICF
• Subjects must have a pathologically confirmed diagnosis of PMF as per the WHO diagnostic criteria or post ET/PV MF (note that all diagnoses must include the presence of at least Grade 2 marrow fibrosis according to the European Consensus on Grading of Bone Marrow Fibrosis (see Table 6) with intermediate -2 or high risk disease according to the IWG-MRT Dynamic International Prognostic Scoring System (DIPSS) (see Table 7)
• A bone marrow biopsy must be performed within the 30 day screening period, however, a bone marrow biopsy obtained within 90 days of screening without intervening treatments and approved by the study chair may suffice.
• Subjects must have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2.
• Life expectancy of at least six months
• At least two weeks must have elapsed between the last dose of any MF-directed drug treatments (including investigational therapies and excluding hydroxyurea) and study enrollment
• Not eligible for ruxolitinib therapy due to a platelet count \<50 x 109/L, previously treated and lack/loss of response as defined by at least one of the following:
• Treatment for ≥3 months with inadequate efficacy response defined as \<10% spleen volume reduction by MRI or \<30% decrease from baseline in spleen length by physical examination or regrowth to these parameters following an initial response; and/or
• Treatment for ≥28 days complicated by either
• i. Development of a red blood cell transfusion requirement (at least 2 units/month for 2 months) ii. National Cancer Institute (NCI) CTCAE grade ≥ 3 AEs of thrombocytopenia, anemia, hematoma, and/or hemorrhage while being treated with a dosage of \< 20 mg BID
• Recovery to ≤ Grade 1 or baseline of any toxicities due to prior systemic treatments, excluding alopecia
• Women of child bearing potential (WCBP), defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least 24 consecutive months if ≤55 years or 12 months if \>55 years, must have a negative serum pregnancy test at screening and cycle 1 day 1 and must agree to use adequate methods of birth control throughout the study. Adequate methods of contraception include use of oral contraceptives or Depo-Provera, with an additional barrier method (diaphragm with spermicidal gel or condoms with spermicide), double-barrier methods (diaphragm with spermicidal gel and condoms with spermicide), partner vasectomy, and total abstinence.
• Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.
• Must have adequate organ function as demonstrated by the following:

You may not qualify if:

• Other invasive malignancies within the last 3 years, except non-melanoma skin cancer and localized cured prostate and cervical cancer.
• Previous exposure to galunisertib, fresolimumab, sotatercept, or luspatercept.
• History of stroke, unstable angina, myocardial infarction, or ventricular arrhythmia requiring medication or mechanical control within the last 6 months
• Have moderate or severe cardiovascular disease:
• have the presence of cardiac disease, including a myocardial infarction within 6 months prior to study entry, unstable angina pectoris, New York Heart Association Class III/IV congestive heart failure, or uncontrolled hypertension
• have documented major ECG abnormalities (not responding to medical treatments)
• Have predisposing conditions that are consistent with development of aneurysms of the ascending aorta or aortic stress (for example, family history of aneurysms, Marfan-Syndrome, bicuspid aortic valve, evidence of damage to the large vessels of the heart documented by CT scan/MRI with contrast)
• Presence of active serious infection;
• Any serious, unstable medical or psychiatric condition that would prevent, (as judged by the Investigator) the subject from signing the informed consent form or any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
• Known history of human immunodeficiency virus (HIV), or known active hepatitis A, B, or C infection
• Organ transplant recipients other than bone marrow transplant
• Women who are pregnant or lactating

Sponsors & Collaborators

• John Mascarenhas: lead
• Formation Biologics: collaborator
• National Cancer Institute (NCI): collaborator
• Myeloproliferative Neoplasm Research Consortium (MPN-RC): collaborator

Study Sites (1)

Icahn School of Medicine at Mount Sinai

New York, New York, 10029, United States

Location

Related Publications (1)

• Varricchio L, Mosoyan G, Elghaity-Beckley S, Mia MB, Handa S, Salib C, Mascarenhas J, Hoffman R. Thrombocytopenia in myelofibrosis is characterized by inflammatory megakaryocytes with reduced G6B expression. Blood. 2025 Sep 25;146(13):1612-1624. doi: 10.1182/blood.2024027363.

  PMID: 40643151 DERIVED

MeSH Terms

Conditions

Primary Myelofibrosis; Fibrosis; Splenomegaly

Condition Hierarchy (Ancestors)

Myeloproliferative Disorders; Bone Marrow Diseases; Hematologic Diseases; Hemic and Lymphatic Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Hypertrophy; Pathological Conditions, Anatomical

Study Officials

• John Mascarenhas, MD

  Icahn School of Medicine at Mount Sinai

  STUDY CHAIR

• Ruben Mesa, MD

  Mays Cancer Center at UT Health

  STUDY CHAIR

• Ronald Hoffman, MD

  Icahn School of Medicine at Mount Sinai

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Associate Professor

Study Record Dates

• First Submitted: March 22, 2019
• First Posted: March 29, 2019
• Study Start: February 15, 2019
• Primary Completion: May 16, 2022
• Study Completion: May 16, 2022
• Last Updated: February 10, 2023

Record last verified: 2023-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)